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IEC: International Eczema Council 
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PARENT JA: PAtient REgistries iNiTiative joint action 
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TO THE EDITOR 
There is an urgent need for novel immuno-modulatory treatments for patients with atopic 
eczema (AE) (syn. ‘atopic dermatitis’); in particular for those with disease recalcitrant to 
topical therapies. The only conventional systemic therapy approved by the European 
Medicines Agency (EMA) is cyclosporine; and only in adults. In the US, only oral 
corticosteroids and dupilumab have Food and Drug Administration (FDA) approval.  
At present, the main evidence to inform clinical practice around conventional systemic 
immuno-modulatory treatments is derived from a rather small body of randomised controlled 
trials (RCTs) (Roekevisch et al., 2014) as well as case series (i.a. (Garritsen et al., 2015; van 
der Schaft et al., 2015)). Despite this, in the absence of approved alternatives, immuno-
modulatory treatments are frequently prescribed as off-label therapies in children and adults, 
as shown in our recent European and North American surveys (Proudfoot et al., 2013; Taylor 
et al., 2016; Totri et al., 2017). Inclusion criteria for clinical trials are stringent; research in 
psoriasis suggests that around 30% of patients on systemic therapies entered into registries (in 
itself a very selected subgroup of all patients on systemic therapy) would not be eligible for a 
clinical trial, underscoring the value of ‘real world’ patient data (Garcia-Doval et al., 2012). 
With the dawn of a new therapeutic era of biologic therapies for AE, some of which have 
shown great promise in placebo-controlled studies and have been approved by the FDA (Beck 
et al., 2014; Simpson et al., 2016; Thaci et al., 2016), we need more evidence with regard to 
effectiveness, safety and cost-effectiveness of such therapies compared to currently used 
treatment modalities, such as phototherapy and systemic immuno-modulatory drugs  
(cyclosporine, methotrexate, azathioprine and others). 
Apart from the need for comparative real life clinical data of conventional and new therapies, 
clinical decision-making requires long-term follow-up data on such treatments to generate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
information on disease control/disease trajectory modification (even after treatment has been 
discontinued) and drug safety, including rare adverse events. Generation of reliable data to 
address these issues requires observation of large patient cohorts for several years.  
Comprehensive health economic evaluation of these different treatments is routinely required 
by many national health technology assessment organizations and third party payers to inform 
the allocation of health care resources. Consequently, independent prospective multi-centre 
registries are a logical step, as has been successfully developed in psoriasis. This is all the 
more important in the light of emerging evidence that suggests that industry-funded post-
marketing studies, which are often conducted to detect rare adverse events, are not improving 
drug safety surveillance (Spelsberg et al., 2017).  
The international TREatment of ATopic eczema (TREAT) Registry Taskforce (www.comet-
initiative.org/studies/details/825?result=true) seeks to find consensus on core domains and 
domain items for AE research registries and to harmonise data collection on patients receiving 
systemic immuno-modulatory therapies, following recently published best-practice guidelines 
of the European Commission funded PAtient REgistries iNiTiative joint action (PARENT JA) 
(http://patientregistrieseu/guidelines) (Zaletel and Kralj, 2015). PARENT was a collaborating 
partner of the TREAT Registry Taskforce. This approach will reduce heterogeneity between 
national registries, enhance interoperability of the national registries, allow direct 
comparability of individual country data and facilitate data pooling between countries. It will 
also help to establish compatible data entry platforms. 
As a first step on this journey, we recently conducted an international eDelphi exercise and a 
consensus meeting among 410 dermatologists, nurses, non-clinical researchers involved in 
AE, pharmaceutical industry representatives, regulatory body representatives and patients   
from 36 countries, including members of the International Eczema Council (IEC), the 
European Taskforce for Atopic Dermatitis (ETFAD), and the International Society for Atopic 
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Dermatitis (ISAD). The study identified a core set of domains and domain items to be 
captured by national AE patient registries (the ‘What’ to measure) (Table 1) (Gerbens et al., 
2017). Further work is currently underway to define how these domains and domain items 
should be measured (the ‘How’ to measure). 
We envisage that eligible patients will be children and adults diagnosed with AE who are 
starting on photo- or systemic immuno-modulatory therapy (conventional immuno-
suppressive therapies as well as new biologics), taking into account the national and local 
eligibility criteria for these specific therapies. Patients receiving intensive topical therapy or 
screen failures for systemic therapy may also be included. Patients will be followed 
independently of stopping therapy or subsequent switch to other therapies. 
We look forward to working with the global dermatology community on this project, 
especially those who routinely treat patients with recalcitrant AE; a disease that accounts for 
more than 20% of total health loss due to skin conditions (Hay et al., 2014) and that has 
shown a health economic impact similar to that of diabetes mellitus and asthma (Williams et 
al., 2008). Ultimately, national cohorts of AE patients on photo- and systemic immuno-
modulatory therapies will inform treatment guidelines and will also act as a resource for 
biomarker discovery and pharmacogenetic and pharmacodynamic research. With novel 
biologic therapies soon to enter our clinical practice, the timing for this project could not be 
better. 
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TABLES 
Table 1. Core set of domains and domain items to be captured in national atopic eczema 
registries* 
DOMAINS DOMAIN ITEMS 
Demographics Date of birth and date of enrolment into registry 
 
Gender 
 
Ethnicity 
 
Educational status 
 
Current occupation or education 
AE diagnosis How diagnosis AE is established 
 
Use of validated diagnostic criteria 
 
Date of onset AE 
Past AE treatments Previous phototherapy 
 
Previous systemic therapy 
 
Previous topical treatments for AE 
 
Previous day hospital care treatments for AE 
(outpatient) 
 
Previous hospitalization for AE 
Current AE treatments Phototherapy 
 
Systemic immunosuppressive therapy 
 
Topical treatments 
 
Amount of topical creams/ointments used per week  
Family history of AE or allergic diseases Family history of AE or allergic diseases 
Allergic co-morbidities Asthma 
 
Allergic rhinoconjunctivitis 
 
Atopic eye disease 
 
Eosinophilic oesophagitis 
 
Food allergies 
 
Contact allergies 
Other co-morbidities Past malignancies 
 
Past serious infections 
Current concomitant medication (i.e. other than 
specific AE medication 
Antihistamines, oral or topical 
 
Topical antibiotics 
 
Oral antibiotics 
 
Immunosuppressives for other inflammatory diseases 
General AE questions Exposures that trigger disease flares 
 
Episodes of skin infection (i.e. folliculitis, HSV, 
molluscum contagiosum) 
 
Days lost from school/college/work 
Baseline physical examination Fitzpatrick skin type 
 
Skin examination 
Baseline physician and patient reported domains Physician-assessed clinical signs 
 
Investigator/physician global assessment 
 
Patient-reported symptoms 
 
Patient global assessment 
 
Generic quality of life score 
 
Skin-specific quality of life score 
 
Patient-reported satisfaction with AE care received 
 
Impact of AE on the family 
Baseline investigations and assessments Medical history (tuberculosis, HIV, hepatitis B or C) 
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Full blood count 
 
Liver function 
 
Kidney profile 
 
Evaluating TPMT level prior to azathioprine use 
Baseline management Reasons for choosing specific treatment (systemic or 
phototherapy) 
 
Routine recording of relative contraindication(s) for 
selected treatment 
Follow up general AE questions Date of death and relation to AE 
 
Change in diagnosis after enrolment (e.g. from AE to 
CTCL) 
Follow up serious adverse events Serious adverse events 
Follow up adverse events that cause stop or switch 
of therapy or change in dosage 
Adverse events that cause stop or switch of therapy or 
change in dosage 
For follow up (serious) adverse events: probability 
of relationship with treatment 
For (serious) adverse events: probability of 
relationship with treatment 
Follow up physical examination Skin examination 
Follow up physician and patient reported domains Physician-assessed clinical signs 
 
Investigator/physician global assessment 
 
Patient-reported symptoms 
 
Patient global assessment 
 
Generic quality of life score 
 
Skin-specific quality of life score 
 
Reporting of disease control, e.g. flares, fully 
controlled weeks 
 
Adherence to treatment between appointments 
 
Patient-reported satisfaction with AE care received 
 
Impact of AE on the family 
Follow up management Reason for switching therapy 
 
Reason for discontinuation of therapy 
Abbreviations: AE, atopic eczema; CTCL, cutaneous T cell lymphoma; HSV, herpes simplex virus; HIV, human 
immunodeficiency virus, TPMT, thiopurine methyltransferase. 
* Results may slightly change after the upcoming ‘How’ to measure meeting. 
 
